The Daily

Reuters reports that the US Commerce Department withdrew a planned rule related to AI chip exports, according to a notice posted on a government website. The headline sounds procedural, but the signal is strategic: export controls are now a living policy surface, not a one-time “final rule.” When the rulebook changes mid-flight, it reshapes how cloud providers plan capacity, how chipmakers forecast demand, and how overseas buyers structure procurement. It also creates a grey zone where companies optimize for compliance today while hedging against tomorrow’s tightening. The next step is less about what was withdrawn and more about what replaces it: expect a revised framework that targets cluster-scale compute and high-risk end uses, not just individual chips. In other words, the policy is moving up the stack.

TechCrunch reports that sales-automation startup Rox AI has reached a reported $1.2B valuation — another datapoint that “AI agents” are becoming a budget line item, not a demo. The enterprise pitch here is less “chatbot” and more “operational throughput”: automate prospecting, follow-ups, data entry, and the glue work that burns SDR time. The risk is obvious: sales is full of edge cases, incentives, and compliance constraints, so reliability matters more than cleverness. The upside is also obvious: if you can attach to revenue and prove incremental pipeline, you get paid.

TechCrunch reports Meta is reportedly weighing layoffs that could reach 20% of headcount — framed as a cost response to escalating AI spend. The important subtext: “AI-first” doesn’t just add new teams; it forces budget tradeoffs across everything else (trust & safety, product experiments, hardware bets, even core social features). If the cut is real, it’s a statement that Meta intends to finance infrastructure and model development by shrinking its operating envelope elsewhere. Next step to watch is whether the company pairs layoffs with a more explicit capex narrative (data centers, GPUs, networking) to keep the market aligned.

CAR-T has always looked best in trials; the real question is how it performs when the patient mix gets messier. This PubMed paper reports real-world outcomes for ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma, with the emphasis on durability and what “standard-of-care” looks like outside a protocol. The study underscores that response rates remain strong even as baseline characteristics (prior lines, frailty, disease burden) diversify. The flip side is operational: manufacturing logistics, bridging therapy, and toxicity management become as determinative as the molecule itself. The next step for the field is not just “better CAR-T” — it’s better systems: earlier referral, predictable slots, and standardized infection prophylaxis pathways.

PROTACs are powerful — and often hard to deliver safely at effective exposures. This PubMed entry describes SonoPIN, a platform built around ultrasound-triggered release to concentrate PROTAC delivery at the tumor site. Conceptually, it’s a nice inversion of the usual “better linker, better PK” story: instead of pushing systemic exposure, localize when and where the payload is active. If this holds up in further studies, it could widen the therapeutic window for degraders that are currently limited by off-target effects. The obvious next step is translational validation: dose, tissue distribution, repeatability of the ultrasound trigger, and whether this can be operationalized beyond a specialized center.

Inovio is doing the ugly, familiar reset: cut costs first, then fight for the program that still has a plausible regulatory lane. Fierce Biotech reports that the company is trimming headcount as it tries to navigate FDA friction around a rare-disease candidate that was supposed to anchor its near-term story. The key issue isn’t just a single data point — it’s the credibility gap that opens when regulators signal uncertainty about endpoints, comparators, or the overall evidentiary package. Management now has to decide what to defend (and how) while preserving enough runway to get a clean readout or an acceptable filing strategy. Expect the next step to be a very explicit “what exactly does FDA want?” update (Type A meeting / written response) and a revised timeline. If they can’t pin down the bar, investors will treat every milestone as optional.

Pfizer is quietly stepping back from Ignite, its attempt to systematically “incubate” external biotech programs inside Pfizer’s machine. The pitch was straightforward: give small teams access to Pfizer’s development, regulatory, and CMC capabilities, then decide whether to partner or acquire. The reality is harder: accelerators struggle when incentives don’t line up and when the parent company’s priorities swing with patent cliffs and portfolio reshuffles. Fierce’s take is that Ignite never became a dependable on-ramp for deal flow at scale, and the program is now winding down rather than expanding. For startups, the lesson is brutal but useful: “access to Big Pharma” is not a strategy unless the commitment survives a budget cycle.

Pierre Fabre Pharmaceuticals says the FDA has agreed to a Type A meeting related to its planned Biologics License Application for tabelecleucel. Type A meetings are the “we need to resolve something now” format — usually triggered by stalled development, dispute resolution, or a path forward question that can’t wait for routine scheduling. The practical implication: the company is trying to lock down what the agency will accept as the core clinical and manufacturing package, and what gaps need to be closed before a submission. If the meeting yields a concrete checklist, it de-risks timing; if it yields another round of data asks, it pushes everything right.

If you’re looking for a Venice trip that isn’t built around queues and “must-see” exhaustion, the Venezia Piano Festival is a clean anchor: it runs 21–26 March 2026 and frames the city as a venue rather than a checklist. Venezia Unica positions it as the first dedicated piano festival in Venice, tied to the cultural ecosystem around La Fenice and the Premio Venezia orbit. The timing is ideal: late March is shoulder-season enough to keep crowds manageable, while the city is already waking up. Practical next step: plan your stay around the festival dates and layer in one museum block per day — Venice is better in small doses.

Wanted in Rome reports the Italian state has purchased a Caravaggio painting for €30 million — a reminder that Italy’s cultural policy is also a tourism strategy. These acquisitions don’t just sit in storage; they become programming: special exhibitions, museum traffic, and regional cultural narratives that pull visitors beyond the usual “Rome-Florence-Venice” loop. The immediate question is where the work will be displayed and under what curatorial framing. For travelers, the meta-play is simple: keep an eye on museum calendars in 2026 — high-profile acquisitions tend to trigger limited-run shows that are worth planning around.

Wenn ihr heute noch einen Plan fürs Wochenende braucht, liefert das FALTER-Kinderprogramm eine starke, konkrete Auswahl — ohne stundenlanges Scrollen. Tipp 1: „Odysseus am Sand“ ist Erzähltheater mit einem Schauspieler, der die Odyssee als Rollen-Feuerwerk spielt; genau die Sorte Bühne, die auch Erwachsene mitnimmt. Tipp 2: „Bravissimo!“ ist eine inszenierte Führung durchs Theater an der Wien (ab 6) mit Musik und Blicken an Orte, die sonst tabu sind — Bühne inklusive. Tipp 3: Der Internationale Tag der Mathematik 2026 an der Akademie der Wissenschaften bringt Vorträge, Mitmachstationen, Workshops und Ausstellungen unter dem Motto „Mathematik und Hoffnung“ (für alle Altersgruppen). Dazu kommen Familienformate wie „House Beat & Family Feet“ oder Babyformate (Babykino, „Mit Baby in die Kunsthalle“). Next step: Pick one “culture” slot and one “movement” slot — dann ist der Tag automatisch rund.

WIENXTRA bündelt das, was in Wien praktisch immer funktioniert: günstige oder kostenlose Aktivitäten, die man ohne große Vorlaufzeit machen kann. Auf der Seite verlinkt sind u.a. die Wochentipps (13.–22. März) sowie eine laufende Liste aktueller Veranstaltungen. Als Beispiele werden konkrete Formate ausgespielt: Familienführungen im Botanischen Garten, eine Gratisrunde Minigolf für Kids, DIY-Workshops in der Stadtbox oder spielerische Angebote in der Spielebox. Der Vorteil ist die niedrige Reibung: Ihr könnt das als „Plan B“ offen lassen und je nach Wetter/Laune entscheiden. Next step: checkt die Details (Ort/Zeitslot) direkt in den jeweiligen Angebotsseiten, dann seid ihr safe.

Wien schaltet in den Frühlingsmodus: MeinBezirk listet die fünf bewilligten Ostermärkte 2026 samt Zeiten und Größenordnung. In Summe sind es 230 Marktstände an fünf Standorten, dazu 47 Gastronomiestände — und damit wieder genau jene Mischung aus Deko, Zucker, Würstel und „nur kurz schauen“, die dann doch zwei Stunden dauert. Konkret: Der Altwiener Ostermarkt auf der Freyung läuft 20. März bis 6. April (täglich 10–20 Uhr; am 29. März ab 9 Uhr). Schönbrunn startet 25. März bis 19. April (10–19 Uhr) mit 88 Ständen (24 Gastro). Kalvarienberg (17.) ist 19. März bis 5. April (werktags 14–19, Wochenende 11–19). Am Hof ist wieder groß gedacht (1., 20. März bis 6. April, 10–21 Uhr) und am Franz‑Jonas‑Platz (21.) läuft der Markt sogar schon seit Ende Februar. Next step: Wer’s entspannt will, geht unter der Woche am frühen Abend; wer mit Kindern unterwegs ist, plant Schönbrunn + Spielplatz als Kombi.

Das „Burgring 1“ hat nach zwei Insolvenzen unter dem früheren Betreiber einen harten Reset hingelegt: neuer Betreiber, Renovierung, aber der alte Name bleibt. Laut MeinBezirk ist das Lokal seit 10. November 2025 wieder offen und positioniert sich als Hybrid aus Café, Restaurant und Bar. Auf der Karte: Frühstück bis 14 Uhr, Wiener Küche, dazu internationale sowie vegetarische und vegane Optionen — plus Cocktails. Innen sind es rund 70 Sitzplätze; im März 2026 soll ein neuer Schanigarten mit 77 Plätzen dazukommen. Öffnungszeiten sind klar (Di–Do 11:30–22, Fr/Sa bis 24, So bis 21). Der nächste Schritt wird sein, ob das Konzept auch außerhalb der „Neustart“-Neugier trägt — dann wird’s ein Fixpunkt.

If you want one game to bottle as “March NBA,” this was it: Lakers–Nuggets goes to overtime and ends on a shot that looks like a physics problem. Yahoo Sports reports Luka Dončić hit a high-difficulty fadeaway in OT to swing the finish and push the Lakers over Denver. The important detail isn’t just the highlight — it’s the context: close games against real opponents are where rotations and late-game hierarchy get stress-tested. Denver has been a measuring stick for years; beating them in crunch time is a confidence signal even if March standings are noisy. Next step: watch whether the Lakers can convert this kind of win into a two-week defensive stretch — the playoffs don’t grade on shotmaking alone.

AP reports Victor Wembanyama returned as San Antonio took care of Charlotte — the kind of “normal” game that still matters when you’re tracking development and health. The Spurs’ season is about reps, not seeding, and Wemby’s availability is the top variable. These post-absence games are also where teams adjust roles: who closes, who initiates, and what the staff is willing to run in late-clock possessions. Next step: pay attention to minutes and usage more than the box score — that’s where the real story sits.